CTLA4 and gastric cancer: Therefore, given the significant morbidity and mortality of gastrectomy, and its potentially negative impact on long-term outcomes in terms of quality of life, there is a strong rationale for investigating PD-(L)1 plus CTLA4 blockade as a definitive treatment and NOM strategy in MSI-H GC in Cohort 2 based on the results of Cohort 1 of the INFINITY Study.